Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsules
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diarrhea
Conditions
Diarrhea
Trial Timeline
Nov 1, 2008 → Nov 1, 2009
NCT ID
NCT00807326About Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsules
Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsules is a approved stage product being developed by Johnson & Johnson for Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT00807326. Target conditions include Diarrhea.
What happened to similar drugs?
8 of 20 similar drugs in Diarrhea were approved
Approved (8) Terminated (4) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00807326 | Approved | Completed |
Competing Products
20 competing products in Diarrhea